Source:http://linkedlifedata.com/resource/pubmed/id/20653333
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
2010-7-26
|
| pubmed:abstractText |
Merck & Co. is developing anacetrapib (MK 0859; MK-0859; MK0859), a selective cholesterol ester transfer protein (CETP) inhibitor, as a treatment for atherosclerosis, hypercholesterolemia, and mixed dyslipidemia. Add-on therapy with anacetrapib is currently being evaluated in a 76-week phase III trial in patients with coronary heart disease (CHD) or CHD risk-equivalent disease in the US, Germany, Spain, and Austria. This review discusses the development history and scientific profile of this new compound.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
1175-3277
|
| pubmed:issnType |
Print
|
| pubmed:volume |
10
|
| pubmed:owner |
NLM
|
| pubmed:pagination |
267-70
|
| pubmed:meshHeading |
pubmed-meshheading:20653333-Atherosclerosis,
pubmed-meshheading:20653333-Cholesterol Ester Transfer Proteins,
pubmed-meshheading:20653333-Clinical Trials as Topic,
pubmed-meshheading:20653333-Coronary Disease,
pubmed-meshheading:20653333-Dyslipidemias,
pubmed-meshheading:20653333-Humans,
pubmed-meshheading:20653333-Hypercholesterolemia,
pubmed-meshheading:20653333-Oxazolidinones
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
Anacetrapib.
|
| pubmed:publicationType |
Journal Article
|